Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
454 Corporation manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These actions are split between 2 distinct examiners, though they are both contained within 1 distinct art unit. This suggests a consistent technical focus despite the involvement of multiple examiners. The busiest examiner is GUSSOW, ANNE, who is currently managing 1 busiest examiner pending action.
With 2 distinct examiners involved, the company must navigate different individual perspectives within the same 1 distinct art unit. The presence of 2 pending office actions indicates an active phase of prosecution for the Biotechnology & Pharmaceuticals filings. Practitioners should note that while the examiners differ, the 1 distinct art unit provides a unified administrative backdrop for the portfolio. This structure requires a strategy that accounts for the individual preferences of GUSSOW, ANNE, who handles 1 busiest examiner pending action, and the other distinct examiner while maintaining a consistent technical narrative across the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FONSECA LOPEZ, FRANCINI ALVARENGA | 1 | 29.6% | +37.1% |
| GUSSOW, ANNE | 1 | 57.9% | +43.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18309775 | PROCESSOR, COMPUTER READABLE MEDIUM AND/OR SOFTWARE FOR IDENTIFYING PROTECTED NUCLEOTIDES INCORPORATED IN SEQUENCING PRIMERS | FONSECA LOPEZ, FRANCINI ALVARENGA | — |
| 18309769 | PREPARING A SAMPLE FOR EVANESCENT WAVE IMAGING | GUSSOW, ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18309775 | PROCESSOR, COMPUTER READABLE MEDIUM AND/OR SOFTWARE FOR IDENTIFYING PROTECTED NUCLEOTIDES INCORPORATED IN SEQUENCING PRIMERS | FONSECA LOPEZ, FRANCINI ALVARENGA | — |
| 18309769 | PREPARING A SAMPLE FOR EVANESCENT WAVE IMAGING | GUSSOW, ANNE | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18309775 | PROCESSOR, COMPUTER READABLE MEDIUM AND/OR SOFTWARE FOR IDENTIFYING PROTECTED NUCLEOTIDES INCORPORATED IN SEQUENCING PRIMERS | FONSECA LOPEZ, FRANCINI ALVARENGA | — | §101§103§112 | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18309769 | PREPARING A SAMPLE FOR EVANESCENT WAVE IMAGING | GUSSOW, ANNE | 1683 | §103§112 | Non-Final OA | — | Pending | Apr 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial